Welcome to our dedicated page for Infusystem Hld news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on Infusystem Hld stock.
InfuSystem Holdings, Inc. (NYSE American: INFU) regularly issues news and press releases that are of interest to investors, analysts and others following the health care services and durable medical equipment space. The company describes itself as a national health care service provider that facilitates outpatient care for durable medical equipment manufacturers and health care providers, with operations organized into Patient Services and Device Solutions platforms.
News items about InfuSystem often include quarterly and annual financial results, where the company discusses net revenues, segment performance for Patient Services and Device Solutions, gross margin trends, cash flow, and Adjusted EBITDA. These releases typically highlight how oncology, pain management and wound therapy within Patient Services, as well as rentals, pump and consumable sales, and biomedical services within Device Solutions, have contributed to overall results.
Another common category of news involves guidance and outlook. InfuSystem has used press releases to provide or reaffirm guidance ranges for net revenue growth and Adjusted EBITDA margin for upcoming fiscal years, and to explain how factors such as revenue mix, information technology projects, and capital expenditures may affect margins and cash flow.
The company also issues announcements about leadership changes and corporate governance, such as the CEO transition disclosed in April 2025, and about participation in investor conferences hosted by firms like ROTH and Craig-Hallum. These items often note that management will host one-on-one or small group meetings with investors.
In addition, InfuSystem uses news releases to communicate regulatory and policy developments that affect its business. For example, an 8-K dated December 10, 2025 references a press release announcing that the Centers for Medicare and Medicaid Services added two electronic infusion pumps used in the company’s Pain Management services business to the list of qualifying products for separate payment under the NOPAIN Act.
Visitors to the INFU news page can review this stream of financial updates, guidance, leadership announcements, conference participation notices and regulatory disclosures to understand how the company describes its performance and strategic priorities over time.
InfuSystem (NYSE American: INFU) will issue preliminary fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 before the market opens. A live investor conference call will be held the same day at 9:00 a.m. ET.
Dial-in numbers, a live webcast via the Investors section at https://ir.infusystem.com/, and a replay (access code 5092611) available through Tuesday, March 3, 2026 were provided. InfuSystem operates two segments: Patient Services (Oncology, Pain Management, Wound Therapy) and Device Solutions, and maintains Centers of Excellence in multiple U.S. states and Ontario, Canada.
InfuSystem (NYSE American: INFU) announced that CEO Carrie Lachance and CFO Barry Steele will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 at the Sheraton New York Times Square Hotel in New York City.
Management is scheduled for in-person one-on-one meetings throughout the day; investors may arrange meetings via their Craig-Hallum representative or contact Lytham Partners at 602-889-9700 or infu@lythampartners.com. The release reiterates InfuSystem’s two-platform business model: Patient Services and Device Solutions, and lists company Centers of Excellence in several U.S. states and Ontario, Canada.
InfuSystem (NYSE:INFU) reported third quarter 2025 results with net revenues of $36.5 million, up 3.3% year-over-year, and net income of $2.3 million (+25%).
Adjusted EBITDA (non-GAAP) was $8.3 million, up 6% with a margin of 22.8%. Gross profit rose 9.3% to $20.8 million and gross margin improved to 57.1%. Year-to-date net operating cash flow was $17.3 million, up 38%.
The Patient Services segment grew 7.6% to $22.4 million (wound care +115% driven by new PCD supplier), while Device Solutions declined 2.9% to $14.1 million. Company liquidity was $54.6 million. Management reaffirmed full-year 2025 guidance of net revenue growth 6–8% and Adjusted EBITDA margin ≥20%.
InfuSystem (NYSE American: INFU) will report third quarter 2025 financial results on Tuesday, November 4, 2025 before the market opens.
The company will host an investor conference call on November 4, 2025 at 9:00 a.m. Eastern Time; dial-in numbers are (833) 366-1127 or (412) 902-6773, and a live webcast will be available in the Investors section at https://ir.infusystem.com/.
A replay will be available at https://ir.infusystem.com/ for 90 days or by calling (855) 669-9658 or (412) 317-0088 with replay access code 7148856 through Tuesday, November 11, 2025. InfuSystem is a national health care service provider operating Patient Services and Device Solutions platforms and maintains Centers of Excellence in multiple U.S. states and Ontario, Canada.
InfuSystem Holdings (NYSE American: INFU), a national healthcare service provider specializing in outpatient care and durable medical equipment services, has announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference. CEO Carrie Lachance and CFO Barry Steele will attend the conference on October 9, 2025, at the Metropolitan Club in New York City.
The company operates under two main platforms: Patient Services (including Oncology, Pain Management, and Wound Therapy) and Device Solutions. Management will be available for one-on-one virtual meetings throughout the conference day, which investors can arrange through their conference representative or Lytham Partners.
InfuSystem Holdings (NYSE American:INFU) reported strong Q2 2025 financial results with record net revenues of $36.0 million, up 7% year-over-year. The company achieved significant improvements across key metrics, including a 262% increase in net income to $2.6 million and a 32% rise in Adjusted EBITDA to $8.0 million.
Patient Services revenue grew 6% to $21.5 million, while Device Solutions revenue increased 8% to $14.5 million. Gross margin expanded by 5.7% to 55.2%, and Adjusted EBITDA margin improved by 4.3% to 22.3%. The company completed $3.5 million in stock repurchases during the quarter.
InfuSystem updated its 2025 guidance, lowering revenue growth expectations to 6-8% from 8-10%, but raising its Adjusted EBITDA margin forecast to 20% or higher, representing a 120 basis point increase over 2024.
InfuSystem Holdings (NYSE American: INFU), a national healthcare service provider specializing in outpatient care and durable medical equipment, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before market open.
The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results. Investors can participate via phone or webcast, with a replay available until August 12, 2025.
InfuSystem operates through two platforms: Patient Services (including Oncology, Pain Management, and Wound Therapy) and Device Solutions, with operations centers across the US and Canada.
InfuSystem Holdings (NYSE American: INFU), a leading national healthcare service provider, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, before market open. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results.
InfuSystem operates under a two-platform model: Patient Services, which includes Oncology, Pain Management, and Wound Therapy businesses, providing clinic-to-home healthcare solutions; and Device Solutions, which supports the Patient Services platform through direct payer rentals, pump and consumable sales, and biomedical services. The company maintains Centers of Excellence across Michigan, Kansas, California, Massachusetts, Texas, and Ontario, Canada.
InfuSystem Holdings (NYSE American: INFU) announced a planned CEO transition, with current President and COO Carrie Lachance set to succeed Richard DiIorio as Chief Executive Officer effective May 19, 2025. DiIorio will remain available as an advisor to support the transition.
Lachance, who joined the company in 2010, has served in various leadership roles including Senior Vice President of Clinical and Customer Services and Territory Sales Manager. She has been President since 2021, COO since 2019, and a board member since 2021.
The company reaffirmed its full-year 2025 guidance, projecting revenue growth of 8-10% and an Adjusted EBITDA margin exceeding 18.8%, surpassing 2024's performance despite planned investments in business applications.